Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$6.67
0.071.06%
al cierre: -
$6.80
0.131.95%
After hour: 4:45 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Evolent Health Inc ha un obiettivo di prezzo di consenso pari a $21.53, stabilito in base alle ultime valutazioni degli analisti di 19. Le ultime 3 valutazioni degli analisti sono state rilasciate da BTIG, Stephens & Co. y Canaccord Genuity il septiembre 30, 2025, septiembre 24, 2025 y septiembre 9, 2025. Con un obiettivo di prezzo medio di $15 tra le BTIG, Stephens & Co. y Canaccord Genuity, c'è un implicito 120.59% upside per Evolent Health Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
BTIG
Stephens & Co.
Canaccord Genuity
Piper Sandler
Truist Securities
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Evolent Health
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
09/30/2025 | 194.12% | BTIG | $20 → $20 | Reiterates | Buy → Buy | |||
09/24/2025 | 32.35% | Stephens & Co. | $9 → $9 | Reiterates | Equal-Weight → Equal-Weight | |||
09/09/2025 | 135.29% | Canaccord Genuity | $16 → $16 | Maintains | Buy | |||
09/09/2025 | 194.12% | BTIG | $20 → $20 | Reiterates | Buy → Buy | |||
08/28/2025 | 164.71% | Piper Sandler | $16 → $18 | Maintains | Overweight | |||
07/17/2025 | 135.29% | Truist Securities | $14 → $16 | Maintains | Buy | |||
06/20/2025 | 91.18% | JMP Securities | $13 → $13 | Reiterates | Market Outperform → Market Outperform | |||
05/13/2025 | 120.59% | Needham | $15 → $15 | Reiterates | Buy → Buy | |||
05/09/2025 | 120.59% | UBS | $14 → $15 | Maintains | Buy | |||
04/28/2025 | 91.18% | JMP Securities | $13 → $13 | Reiterates | Market Outperform → Market Outperform | |||
04/10/2025 | 105.88% | Truist Securities | $15 → $14 | Maintains | Buy | |||
03/10/2025 | 76.47% | JP Morgan | $13 → $12 | Maintains | Overweight | |||
02/24/2025 | 91.18% | Citizens Capital Markets | $12 → $13 | Maintains | Market Outperform | |||
02/21/2025 | 135.29% | Piper Sandler | $17 → $16 | Reiterates | Overweight → Overweight | |||
02/21/2025 | 120.59% | Needham | $15 → $15 | Reiterates | Buy → Buy | |||
02/14/2025 | 76.47% | JMP Securities | $12 → $12 | Reiterates | Market Outperform → Market Outperform | |||
02/12/2025 | 120.59% | Needham | $15 → $15 | Reiterates | Buy → Buy | |||
01/28/2025 | 91.18% | JP Morgan | $15 → $13 | Maintains | Overweight | |||
01/24/2025 | 76.47% | JMP Securities | $18 → $12 | Maintains | Market Outperform | |||
01/24/2025 | 164.71% | Oppenheimer | $28 → $18 | Maintains | Outperform | |||
01/23/2025 | 135.29% | Canaccord Genuity | $23 → $16 | Maintains | Buy | |||
01/22/2025 | 120.59% | Truist Securities | $20 → $15 | Maintains | Buy | |||
01/21/2025 | 76.47% | Stephens & Co. | $16 → $12 | Maintains | Equal-Weight | |||
01/16/2025 | 105.88% | UBS | $27 → $14 | Maintains | Buy | |||
01/15/2025 | 120.59% | Needham | $15 → $15 | Reiterates | Buy → Buy | |||
01/14/2025 | 150% | RBC Capital | $20 → $17 | Maintains | Outperform | |||
01/13/2025 | 194.12% | Truist Securities | $24 → $20 | Maintains | Buy | |||
01/10/2025 | 164.71% | Citigroup | $21 → $18 | Maintains | Buy | |||
01/10/2025 | 164.71% | JMP Securities | $27 → $18 | Maintains | Market Outperform | |||
01/10/2025 | 120.59% | Needham | → $15 | Initiates | → Buy | |||
11/22/2024 | 120.59% | JP Morgan | $45 → $15 | Maintains | Overweight | |||
11/18/2024 | 311.76% | Oppenheimer | $34 → $28 | Maintains | Outperform | |||
11/13/2024 | 208.82% | Citigroup | $33 → $21 | Maintains | Buy | |||
11/12/2024 | 194.12% | RBC Capital | $20 → $20 | Reiterates | Outperform → Outperform | |||
11/11/2024 | 252.94% | Truist Securities | $33 → $24 | Maintains | Buy | |||
11/11/2024 | 179.41% | Barclays | $39 → $19 | Maintains | Overweight | |||
11/08/2024 | 400% | Oppenheimer | $45 → $34 | Maintains | Outperform | |||
11/08/2024 | 135.29% | Stephens & Co. | → $16 | Downgrade | Overweight → Equal-Weight | |||
10/29/2024 | 385.29% | Citigroup | $35 → $33 | Maintains | Buy | |||
10/11/2024 | 414.71% | Keybanc | → $35 | Initiates | → Overweight | |||
10/08/2024 | 517.65% | RBC Capital | $42 → $42 | Reiterates | Outperform → Outperform | |||
08/27/2024 | 385.29% | Truist Securities | $33 → $33 | Maintains | Buy | |||
08/26/2024 | 517.65% | RBC Capital | $42 → $42 | Reiterates | Outperform → Outperform | |||
08/19/2024 | 561.76% | JP Morgan | $36 → $45 | Maintains | Overweight | |||
08/09/2024 | 355.88% | JMP Securities | $34 → $31 | Maintains | Market Outperform | |||
08/09/2024 | 385.29% | Truist Securities | $28 → $33 | Upgrade | Hold → Buy | |||
07/30/2024 | 517.65% | Stephens & Co. | $42 → $42 | Reiterates | Overweight → Overweight | |||
05/10/2024 | 502.94% | Canaccord Genuity | $44 → $41 | Maintains | Buy | |||
05/10/2024 | 400% | JMP Securities | $38 → $34 | Maintains | Market Outperform | |||
04/22/2024 | 488.24% | Citigroup | → $40 | Initiates | → Buy | |||
03/28/2024 | 547.06% | Canaccord Genuity | $45 → $44 | Maintains | Buy | |||
03/15/2024 | 664.71% | JP Morgan | $53 → $52 | Maintains | Overweight | |||
03/01/2024 | 561.76% | Oppenheimer | → $45 | Initiates | → Outperform | |||
02/23/2024 | 458.82% | JMP Securities | $37 → $38 | Maintains | Market Outperform | |||
02/23/2024 | 561.76% | Canaccord Genuity | $47 → $45 | Maintains | Buy | |||
12/06/2023 | 444.12% | JMP Securities | → $37 | Initiates | → Market Outperform | |||
11/28/2023 | 517.65% | RBC Capital | $44 → $42 | Maintains | Outperform | |||
11/14/2023 | 400% | Truist Securities | $36 → $34 | Maintains | Hold | |||
10/16/2023 | 576.47% | UBS | → $46 | Initiates | → Buy | |||
08/14/2023 | 591.18% | Guggenheim | → $47 | Reiterates | Buy → Buy | |||
06/26/2023 | 591.18% | Guggenheim | $50 → $47 | Maintains | Buy | |||
05/24/2023 | 547.06% | RBC Capital | → $44 | Reiterates | → Outperform | |||
05/04/2023 | 488.24% | Stephens & Co. | → $40 | Reiterates | → Overweight | |||
04/12/2023 | 488.24% | Stephens & Co. | → $40 | Initiates | → Overweight | |||
02/23/2023 | 547.06% | RBC Capital | → $44 | Reiterates | → Outperform | |||
01/30/2023 | 767.65% | Cowen & Co. | $57 → $59 | Maintains | Outperform | |||
11/18/2022 | 738.24% | Cowen & Co. | $52 → $57 | Maintains | Outperform | |||
11/04/2022 | 385.29% | Piper Sandler | $40 → $33 | Maintains | Overweight | |||
11/01/2022 | 385.29% | Truist Securities | → $33 | Initiates | → Hold |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Evolent Health (EVH)?
El último precio objetivo de Evolent Health (NYSE:EVH) fue comunicado por BTIG el septiembre 30, 2025. La firma de analistas fijó un precio objetivo para $20.00 que espera EVH a rise dentro de 12 meses (un posible 194.12% upside). 38 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Evolent Health (EVH)?
La última calificación de analistas para Evolent Health (NYSE:EVH) fue proporcionada por BTIG, y Evolent Health reiterado su buy calificación.
¿Cuándo se produjo la última revisión al alza de Evolent Health (EVH)?
La última revisión al alza de Evolent Health Inc se produjo en agosto 9, 2024, cuando Truist Securities elevó su precio objetivo a $33. Truist Securities anteriormente tenía a hold para Evolent Health Inc.
¿Cuándo fue la última revisión a la baja de Evolent Health (EVH)?
La última revisión a la baja de Evolent Health Inc se produjo en noviembre 8, 2024, cuando Stephens & Co. cambió su precio objetivo de N/A a $16 para Evolent Health Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Evolent Health (EVH)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Evolent Health, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Evolent Health se registró el septiembre 30, 2025, por lo que la próxima calificación estará disponible en torno al septiembre 30, 2026.
¿Es correcta la calificación de los analistas sobre Evolent Health (EVH)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Evolent Health (EVH) fue un reiterado con un precio objetivo de $20.00 a $20.00. El precio actual al que cotiza Evolent Health (EVH) es de $6.80, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.